ASX:OSP

Stock Analysis Report

Executive Summary

Osprey Medical, Inc., a commercial stage company, focuses on protecting patients from the harmful effects of X-ray dye used during commonly performed angiographic imaging procedures in the United States and internationally.

Snowflake

Fundamentals

Adequate balance sheet with questionable track record.

Share Price & News

How has Osprey Medical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: OSP's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

2.3%

OSP

4.9%

AU Medical Equipment

0.9%

AU Market


1 Year Return

-66.7%

OSP

46.9%

AU Medical Equipment

16.3%

AU Market

Return vs Industry: OSP underperformed the Australian Medical Equipment industry which returned 46.9% over the past year.

Return vs Market: OSP underperformed the Australian Market which returned 16.3% over the past year.


Shareholder returns

OSPIndustryMarket
7 Day2.3%4.9%0.9%
30 Day-10.0%5.0%1.4%
90 Day-27.4%13.4%6.0%
1 Year-66.7%-66.7%49.3%46.9%23.0%16.3%
3 Year-89.9%-90.0%69.5%62.0%41.6%22.3%
5 Year-92.1%-92.2%159.3%138.5%57.7%22.5%

Price Volatility Vs. Market

How volatile is Osprey Medical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Osprey Medical undervalued compared to its fair value and its price relative to the market?

0.8x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate OSP's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate OSP's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: OSP is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: OSP is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate OSP's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: OSP is good value based on its PB Ratio (0.8x) compared to the AU Medical Equipment industry average (4.9x).


Next Steps

Future Growth

How is Osprey Medical forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

13.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OSP is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: OSP is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: OSP is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: OSP's revenue (48.1% per year) is forecast to grow faster than the Australian market (3.7% per year).

High Growth Revenue: OSP's revenue (48.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if OSP's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Osprey Medical performed over the past 5 years?

-13.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: OSP has high quality earnings.

Growing Profit Margin: OSP's current net profit margins (-569.7%) are higher than last year (-776.1%).


Past Earnings Growth Analysis

Earnings Trend: OSP is unprofitable, and losses have increased over the past 5 years at a rate of -13.4% per year.

Accelerating Growth: Unable to compare OSP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OSP is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (29.5%).


Return on Equity

High ROE: OSP has a negative Return on Equity (-108.22%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Osprey Medical's financial position?


Financial Position Analysis

Short Term Liabilities: OSP's short term assets ($17.8M) exceeds its short term liabilities ($1.9M)

Long Term Liabilities: OSP's short term assets (17.8M) exceeds its long term liabilities (435.4K)


Debt to Equity History and Analysis

Debt Level: OSP is debt free.

Reducing Debt: OSP has not had any debt for past 5 years.


Balance Sheet

Inventory Level: OSP has a low level of unsold assets or inventory.

Debt Coverage by Assets: OSP's debt is covered by short term assets (assets are 1.6036254522834E+17x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: OSP has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: OSP has less than a year of cash runway if free cash flow continues to reduce at historical rates of -18.2% each year


Next Steps

Dividend

What is Osprey Medical's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.4%markettop25%5.6%industryaverage1.5%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate OSP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate OSP's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OSP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OSP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OSP's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

What is the CEO of Osprey Medical's salary, the management and board of directors tenure and is there insider trading?

7.3yrs

Average management tenure


CEO

Mike McCormick (57yo)

9.7yrs

Tenure

0

Mr. Michael McCormick, also known as Mike has been the President and Chief Executive Officer of Osprey Medical Inc. since March 2010. Mr. McCormick has more than 20 years of experience in the medical devic ...


Management Age and Tenure

7.3yrs

Average Tenure

54.5yo

Average Age

Experienced Management: OSP's management team is seasoned and experienced (7.3 years average tenure).


Board Age and Tenure

8.5yrs

Average Tenure

58.5yo

Average Age

Experienced Board: OSP's board of directors are considered experienced (8.5 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SellUS$169,65906 Sep 19
Kinetic Investment Partners Limited
EntityCompany
Shares3,513,691
Max PriceUS$0.048
BuyUS$401,54020 Jun 19
Kinetic Investment Partners Limited
EntityCompany
Shares4,364,609
Max PriceUS$0.092
BuyUS$960,26613 Jun 19
Kinetic Investment Partners Limited
EntityCompany
Shares8,814,371
Max PriceUS$0.11
SellUS$960,26613 Jun 19
Kinetic Investment Partners Limited
EntityCompany
Shares8,814,371
Max PriceUS$0.11
BuyUS$20,36207 Mar 19
Neville Mitchell
EntityIndividual
Role
Member of the Board of Directors
Non-Executive Director
Shares185,809
Max PriceUS$0.11
BuyUS$1,491,00514 Dec 18
AustralianSuper Pty. Ltd.
EntityCompany
Shares9,318,749
Max PriceUS$0.16
BuyUS$21,03402 Dec 18
Neville Mitchell
EntityIndividual
Role
Member of the Board of Directors
Non-Executive Director
Shares135,700
Max PriceUS$0.15

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 23.1%.


Management Team

  • Vic Fabano (57yo)

    Vice President of Operations & IT

    • Tenure: 7.3yrs
  • Mike McCormick (57yo)

    President

    • Tenure: 9.7yrs
  • Brendan Case

    Secretary

    • Tenure: 0yrs
  • J. Shapland

    Co-Founder

    • Tenure: 0yrs
  • Nancy Ness

    VP of Finance & CFO

    • Tenure: 9.5yrs
  • Jim Surek (52yo)

    VIce President of Sales

    • Tenure: 0.7yrs
  • Doug Schoenberg (49yo)

    Vice President of Marketing

    • Tenure: 0yrs
  • Melanie Hess

    Vice President of Regulatory Affairs

    • Tenure: 1.8yrs

Board Members

  • John Erb (70yo)

    Non-Executive Chairman

    • Tenure: 0yrs
  • Mike McCormick (57yo)

    President

    • Tenure: 9.7yrs
  • Neville Mitchell (60yo)

    Non-Executive Director

    • Tenure: 7.3yrs
  • Andy Jane (57yo)

    Non-Executive Director

    • Tenure: 7yrs
  • Gregg Stone (62yo)

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • Chris Nave (44yo)

    Non-Executive Director

    • Tenure: 14.1yrs
  • Steve Bailey

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • David Kaye

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • David Lee

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • James Tumlin

    Member of Medical Advisory Board

    • Tenure: 0yrs

Company Information

Osprey Medical, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Osprey Medical, Inc.
  • Ticker: OSP
  • Exchange: ASX
  • Founded: 2005
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: AU$19.431m
  • Shares outstanding: 431.80m
  • Website: https://www.ospreymed.com

Location

  • Osprey Medical, Inc.
  • 5600 Rowland Road
  • Suite 250
  • Minnetonka
  • Minnesota
  • 55343
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
OSPASX (Australian Securities Exchange)YesNPV (CHESS DEPOSITARY INTERESTS)AUAUDMay 2012
OSPCHIA (Chi-X Australia)YesNPV (CHESS DEPOSITARY INTERESTS)AUAUDMay 2012

Biography

Osprey Medical, Inc., a commercial stage company, focuses on protecting patients from the harmful effects of X-ray dye used during commonly performed angiographic imaging procedures in the United States an ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/17 10:34
End of Day Share Price2019/11/15 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.